Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in moderately to severely active ulcerative colitis in Japanese patients
NCT03915769Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ozanimod in ulcerative colitis (UC), sponsored by Celgene Corporation. Started Jun 2019; status: completed.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03915769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915769.